Abstract
In order to develop an integrated pharmacokinetic/viral dynamic (PK/VD) model to predict long-term virological response rates to daclatasvir (DCV) and asunaprevir (ASV) combination therapy in patients infected with genotype 1 (GT1) chronic hepatitis C virus (HCV), a systematic publication search was conducted for DCV and ASV administered alone and/or in combination in healthy subjects or patients with GT1 HCV infection. On the basis of a constructed meta-database, an integrated PK/VD model was developed, which adequately described both DCV and ASV PK profiles and viral load time curves. The IC50 values of DCV and ASV were estimated to be 0.041 and 2.45 μg/L, respectively, in GT1A patients. A sigmoid Emax function was applied to describe the antiviral effects of DCV and ASV, depending on the drug concentrations in the effect compartment. An empirical exponential function revealed that IC50 changing over time described drug resistance in HCV GT1A patients during DCV or ASV monotherapy. Finally, the PK/VD model was evaluated externally by comparing the expected and observed virological response rates during and post-treatment with DCV and ASV combination therapy in HCV GT1B patients. Both the rates were in general agreement. Our PK/VD model provides a useful platform for the characterization of pharmacokinetic/pharmacodynamic relationships and the prediction of long-term virological response rates to aid future development of direct acting antiviral drugs.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST . Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333–42.
Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 2012; 7: e39652.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL. Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65.
Young JL . Chronic fatigue syndrome: 3 cases and a discussion of the natural history of attention-deficit/hyperactivity disorder. Postgraduate Med 2013; 125: 162–8.
Shahid I, WH AL, Hafeez MH, Hassan S . Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol 2014: 1–13.
Schinazi R, Halfon P, Marcellin P, Asselah T . HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34: 69–78.
Eley T, Garimella T, Li W, Bertz RJ . Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions. Clin Pharmacokinet 2015; 54: 1205–22.
Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, et al. Population Pharmacokinetic analysis of daclatasvir in subjects with chronic hepatitis C virus infection. Clin Pharmacokinet 2017 Jan 9. doi: 10.1007/s40262-016-0504-2.
Sato K, Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S, et al. Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases 2016; 4: 88–93.
Au JS, Pockros PJ . Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014; 95: 78–88.
Schaefer EAK, Chung RT . Anti-hepatitis C virus drugs in development. Gastroenterology 2012; 142: 1340–50.e1.
Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, et al. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014; 57: 1730–52.
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597–605.
Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 2010; 87: 706–13.
Koizumi Y, Iwami S . Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs. Theo Biol Med Model 2014; 11: 41.
Perelson AS, Herrmann E, Micol F, Zeuzem S . New kinetic models for the hepatitis C virus. Hepatology 2005; 42: 749–54.
Colombatto P, Civitano L, Oliveri F, Coco B, Ciccorossi P, Flichman D, et al. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003; 8: 519–30.
Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, et al. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. J Viral Hepatitis 2008; 15: 591–9.
Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS . Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922–4.
Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A 2013; 110: 3991–6.
Laouenan C, Guedj J, Mentre F . Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach. BMC Med Res Methodol 2013; 13: 60.
Guedj J, Dahari H, Shudo E, Smith P, Perelson AS . Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012; 55: 1030–7.
Canini L, Chatterjee A, Guedj J, Lemenuel-Diot A, Brennan B, Smith PF, et al. A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV. Antivir Ther 2015; 20: 469–77. doi: 10.3851/IMP2879.
Rong L, Dahari H, Ribeiro RM, Perelson AS . Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2: 30ra32.
Nguyen TH, Mentre F, Levi M, Yu J, Guedj J . A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response. Clin Pharmacol Ther 2014; 96: 599–608.
Comings DE, Comings BG . A controlled family history study of Tourette's syndrome, I: Attention-deficit hyperactivity disorder and learning disorders. J Clin Psychiatry 1990; 51: 275–80.
Neumann AU . Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- therapy. Science 1998; 282: 103–7.
Ke R, Loverdo C, Qi H, Olson CA, Wu NC, Sun R, et al. Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrobial Chemother 2014; 69: 724–7.
McCormick AL, Wang L, Garcia-Diaz A, Macartney MJ, Webster DP, Haque T . Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4. Antivir Ther 2015; 20: 81–5.
Nettles RE, Chien C, Chung E, Persson A, Gao M, Belema M, et al. BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study. 20th Conference of the Asian Pacific Association for the Study of the Liver. Beijing, China: NATAP.org 2010.
Bifano M, Sevinsky H, Bedford B, Coumbis J, Eley T, Huang SP, et al. Coadministration of BMS-790052 and BMS-650032 does not result in a cinically meaningful pharmacokinetic interaction in healthy subjects. 61th Annual Meeting of the American Association for the Study of Liver Diseasesed. Hynes Convention Center, Boston, MA.: NATAP.org 2010.
Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: 1956–65.
Shiozaki T, Ueno T, Nagashima H, Yamahira N, Hiraoka M, Eley T, et al. Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects. Int J Clin Pharmacol Ther 2015; 53: 292–302.
Bifano M, Sevinsky H, Persson A, Chung E, Wind-Rotolo M, Hwang C, et al. Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects. 62th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA. USA: NATAP.org 2011.
Eley T . Pharmacokinetics of the NS3 protease inhibitor, asunaprevir (ASV, BMS-650032), in phase I studies in subjects with or without chronic hepatitis C. Clin Pharmacol Drug Develop 2013; 2: 316–27.
Pasquinelli C, Eley T, Villegas C, Sandy K, Mathias E, Wendelburg P, et al. Safety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS- 650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection. 60th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA.: NATAP.org 2009.
Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrobial Agents Chemother 2012; 56: 1838–44.
Eley T, He B, Huang S, Stonier M, Bedford W, Kandoussi H, et al. Effect of multiple-dose ketoconazole and the effect of multiple-dose rifampin on the pharmacokinetics (PK) of the NS3 protease inhibitor asunaprevir. 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Cambridge, MA, USA 2013.
Eley T, Han YH, Huang SP, He B, Li W, Bedford W, et al. Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease. Clin Pharmacol Ther 2015; 97: 159–66.
Garimella T, He B, Luo WL, Colston E, Zhu K, Kandoussi H, et al. Asunaprevir pharmacokinetics and safety in subjects with impaired renal function. 64rd Annual Meeting of the American Association for the Study of Liver Diseases. Washington, DC. USA 2013.
Bifano M, Sevinsky H, Bedford B, Coumbis J, Eley T, Huang SP, et al. Coadministration of BMS-790052 and BMS-650032 does not result in a clinically meaningful pharmacokinetic interaction in healthy subjects. 61th Annual Meeting of the American Association for the Study of Liver Diseases ed. Boston, MA. USA: NATAP.org 2010.
Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216–24.
Lok AS, Hezode C, Lawitz EJ, Bourliere M, Everson GT, Marcellin P, et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A Inhibitor) and asunaprevir (ASV; NS3 Inhibitor[protease]) with or without peginterferon Alfa-2a/ribavirin (PEG/RBV) and triple all-oral daclatasvir+asunaprevir+Rbv (gt1a/1b). The 2013 Annual Meeting of the Asian Pacific Association for the Study of the Liver. Singapore: NATAP 2013.
Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655–62.
Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646–54.
Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742–8.
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083–91.
Karino Y, Suzuki F, Suzuki Y, Toyota J, Chayama K, Kawakami Y, et al. All-oral dual combination of daclatasvir plus asunaprevir compared with telaprevir plus peginterferon Alfa/ribavirin in treatment-naive Japanese patients chronically infected with HCV genotype 1b. The AI447031 Study 24th Conference of the Asian Pacific Association for the Study of the Livered. Brisbane, Australia 2014.
Wei L, Zhang MX, Xu M, Chuang WL, Lu W, Xie W, et al. Daclatasvir and asunaprevir in non-Japanese asian patients with chronic HCV genotype 1b infection who are ineligible for or intolerant to interferon-alfa therapies with or without ribavirin: phase 3 SVR12 interim results. 66th Annual Meeting of the American Association for the Study of Liver Diseasesed. Boston, MA, USA 2015.
Lee C . Daclatasvir: potential role in hepatitis C. Drug Design Develop Ther 2013; 7: 1223–33.
Eley T, Sverdlov O, He B, Bedford B, Kandoussi H, Perrone R, et al. Improved bioavailability and mitigated food effect for asunaprevir (ASV) utilizing a lipid-based formulation: similar exposure with 100 mg BID softgel capsule (SGC) relative to 200 mg BID of phase 2 tablet. Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco: ICAAC 2012.
Wang C, Sun JH, O'Boyle DR, 2nd, Nower P, Valera L, Roberts S, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrobial Agents Chemother 2013; 57: 2054–65.
Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–7.
Dahari H, Ribeiro RM, Perelson AS . Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007; 46: 16–21.
Canini L, Perelson AS . Viral kinetic modeling: state of the art. J Pharmacokinet Pharmacodyn 2014; 41: 431–43.
Dahari H, Guedj J, Perelson AS, Layden TJ . Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr Hepatitis Rep 2011; 10: 214–27.
Poordad F, Reddy KR, Martin P . Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infectious Dis 2008; 46: 78–84.
Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S . Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69–75.
Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G . Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425–33.
Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96–100.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary information is available at the website of Acta Pharmacologica Sinica.
Supplementary information
Supplementary Information
Supplementary Figure S1–S4 (DOC 128 kb)
Rights and permissions
About this article
Cite this article
Wang, Hc., Ren, Yp., Qiu, Y. et al. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. Acta Pharmacol Sin 39, 140–153 (2018). https://doi.org/10.1038/aps.2017.84
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2017.84
